

**Date and Time:** 31<sup>st</sup> August and 1<sup>st</sup> September 2011, 10:00-16:30

**Minutes:** Confirmed

**Guideline Development Group Meeting 1 Osteoporosis: assessing the risk of fragility fracture**

**Place:** Boardroom, National Clinical Guideline Centre (NCGC)  
180 Great Portland Street  
London W1W 5QZ  
UK

**Present:** **Peter Barry** (GDG Chair) (Honorary lecturer in child health, University of Leicester)  
**Terry Aspray** (Consultant in Metabolic Bone Disease, Freeman Hospital, Newcastle)  
**Kathleen Briers** (Patient/Carer Member)  
**Gary Collins** (Senior Medical Statistician, University of Oxford)  
**Juliet Compston** (Professor of Bone Medicine, University of Cambridge)  
(Present on Day 1 only)  
**Frances Dockery** (Consultant Geriatrician, St. Thomas's Hospital, London)  
**Sheila Ruddick** (Osteoporosis Specialist Nurse, County Durham and Darlington Foundation Trust)  
**Peter Selby** (Consultant Physician, Senior Lecturer in Medicine, Manchester Royal Infirmary)  
**David Stephens** (Portfolio GP, Scotland)  
**Angela Thornhill** (Patient/Carer Member)  
**Jonathan Tobias** (Professor of Rheumatology, University of Bristol)  
**Elisabetta Fenu** (Senior Health Economist, NCGC)  
**Lina Gulhane** (Senior Information Scientist, NCGC)  
**Rosa Lau** (Research Fellow, NCGC)  
**Lilian Li** (Health Economist, NCGC)  
**Norma O'Flynn** (Clinical Director, NCGC)  
**Silvia Rabar** (Senior Project Manager and Research Fellow, NCGC)  
**Sharon Swain** (Senior Research Fellow, NCGC)  
**Maggie Westby** (Clinical Effectiveness Lead, NCGC)

**In attendance:**

NICE Staff: Michael Heath	Guideline Commissioning Manager	
Barbara Meredith	Patient and Public Involvement Programme	(Present on Day 1 only)
Michelle Wallwin	Senior Medical Editor	(Present on Day 1 only)

**Observers:**

Thomas Madden Richard Whittome	Information Scientist, NCGC	(Present on Day 1 only)
-----------------------------------	-----------------------------	-------------------------

**Notes**

## Notes

### Day 1

1. Peter Barry welcomed the group to the first meeting of this GDG. Apologies were received from Sarah Chalmers Patient and Public Involvement Programme, NICE. The Chair asked all GDG members to declare any relevant conflicts of interest. Conflicts of interest were declared as follows:  
Juliet Compston declared: Personal pecuniary interest: Advisory board/speaking commitments for Amgen, Novartis, MSD, Serner, Wamer-Chillott, Gilead, Glaxo SmithKline & Nylomed. Non-personal pecuniary interest: Grant funding from GlaxoSmith Kline. Personal non-pecuniary interest: Chairman of National Osteoporosis Guideline Group.  
Sheila Ruddick declared: Personal pecuniary interest: Received reimbursement of expenses from GSK April 2011. Received reimbursement of expenses (BSR Conference) April 2011 AMGEN.  
Peter Selby declared: Non-personal pecuniary interest: Amgen supporting departmental research in Primary hyperparathyroidism. Personal non-pecuniary interest: Former Trustee of NOS, currently on clinical & scientific committee. Author of NOGG.  
David Stephens declared: Personal non-pecuniary interest: member of the SIGN GDG on Osteoporosis.  
Angela Thornhill declared: Personal pecuniary interest: Voluntary role - stepped down from chair Nottingham support group of NOS in March 2011, Member of NOS.
2. The Chair introduced Norma O'Flynn, clinical director at NCGC, who gave presentation on the NCGC and declaration of interests. The Chair thanked Norma O'Flynn for her presentation.
3. The Chair introduced Michael Heath, guideline commissioning manager at NICE, who gave a presentation on the role of the guideline commissioning manager in guideline development. The Chair thanked Michael Heath for his presentation.
4. The Chair introduced Barbara Meredith, Patient and Public Involvement Programme manager at NICE, who gave a presentation on the on the role of the patient/carer members in guideline development. The Chair thanked Barbara Meredith for her presentation.
5. The Chair introduced Michelle Wallwin, Senior Medical Editor at NICE, who gave a presentation on the on the role of the editor in guideline development. The Chair thanked Michelle Wallwin for her presentation.
6. The Chair introduced Lina Gulhane, Senior Information Scientist at NCGC, who gave a presentation on the on the role of the information scientist, literature search and protocol development. The Chair thanked Lina Gulhane for her presentation.
7. The Chair introduced Lilian Li, Health Economist at NCGC, who gave a presentation on health economics for guideline development, and took questions from the group. The Chair thanked Lilian Li for her presentation.
8. The Chair gave a presentation on the scope for the guideline and took questions from the group.
9. The Chair introduced Maggie Westby, Clinical Effectiveness Lead at NCGC, who gave an introductory presentation to prognostic studies, and took questions from the group. The Chair thanked Maggie Westby for her presentation.
10. The Chair introduced Rosa Lau, Research Fellow at NCGC, who gave a presentation on the clinical questions, and took questions from the group. The GDG then discussed the clinical questions in relation to this guideline. The Chair thanked Rosa Lau for her

## **Notes**

presentation.

11. The Chair introduced Silvia Rabar, Senior Project Manager and research Fellow at NCGC, who gave a presentation on Claromentis, a web-based intranet site for document sharing, version control and forums. The Chair thanked Silvia Rabar for her presentation.
12. There was no other business to discuss. The Chair closed the meeting and thanked everybody for attending.

## **Day 2**

13. The Chair reconvened the meeting.
14. The Chair introduced Maggie Westby, Clinical Effectiveness Lead at NCGC, who gave a presentation on the methodology for prognostic and diagnostic reviews and the planned approach to the review of the evidence. The GDG then discussed the issues presented in relation to this guideline. The Chair thanked Maggie Westby for her presentation.
15. The Chair introduced Silvia Rabar, Senior Project Manager and Research Fellow at NCGC, who gave a presentation on the clinical evidence for the FRAX assessment tools to evaluate fracture risk of patients, and took questions from the group. The GDG then discussed the issues presented in relation to this guideline. The Chair thanked Silvia Rabar for her presentation.
16. The Chair introduced Rosa Lau, Research Fellow at NCGC, who gave a presentation on the clinical evidence for the QFracture assessment tools to evaluate fracture risk of patients, and took questions from the group. The GDG then discussed the issues presented in relation to this guideline. The Chair thanked Rosa Lau for her presentation.
17. There was no other business to discuss. The Chair closed the meeting and thanked everybody for attending.

## **Date, time and venue of the next meeting**

18. Wednesday 5<sup>th</sup> October 2011, 10:00-16:30, at the NCGC, 180 Great Portland Street, London W1W 5QZ